ARWR
HealthcareArrowhead Pharmaceuticals, Inc.
$55.17+0.16 (+0.29%)
Prev Close
$55.01
Open
$55.86
High
$56.57
Low
$54.02
Volume
1.53M
Market Cap
$8.28B
P/E
36.06
Div Yield
—
Over the past 12 months, insider activity at Arrowhead Pharmaceuticals, Inc. (ARWR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 21 insider sales totaling $43.98M. The most recent insider transaction was by Hamilton James C (officer: Chief Medical Officer), who sold $641.9K worth of shares on Mar 9, 2026. Arrowhead Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $8.28B.
Buys (12M)
0
$0.00
Sells (12M)
21
$43.98M
Net Activity
Net Seller
$43.98M
Active Insiders
8
last 12 mo
ARWR Price Chart
ARWR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026↗ | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $64.19 | $641.9K | 236,958 |
| Jan 5, 2026↗ | Anzalone Christopher Richard | director, officer: Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 3,798,510 |
| Jan 5, 2026↗ | Hamilton James C | officer: Chief Medical Officer | Sell | 80,328 | $63.11 | $5.07M | 207,497 |
| Jan 5, 2026↗ | O'Brien Patrick | officer: COO | Sell | 48,593 | $63.12 | $3.07M | 520,033 |
| Jan 2, 2026↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 0 |
| Dec 31, 2025↗ | O'Brien Patrick | COO | Sell | 49,493 | $63.11 | $3.12M | 0 |
| Dec 29, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,726 | $69.13 | $3.58M | 0 |
| Dec 26, 2025↗ | Ferrari Mauro | Director | Sell | 7,530 | $70.00 | $527.1K | 0 |
| Dec 19, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,031 | $68.04 | $1.77M | 0 |
| Dec 19, 2025↗ | OLUKOTUN ADEOYE Y | Director | Sell | 10,000 | $67.66 | $676.6K | 0 |
| Dec 19, 2025↗ | Vakiener Victoria | Director | Sell | 10,040 | $67.68 | $679.5K | 0 |
| Dec 19, 2025↗ | Waddill William D. | Director | Sell | 8,367 | $67.65 | $566.0K | 0 |
| Dec 17, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 85,000 | $64.04 | $5.44M | 0 |
| Dec 12, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 184,298 | $67.00 | $12.35M | 0 |
| Dec 5, 2025↗ | PERRY MICHAEL S | Director | Sell | 16,250 | $61.03 | $991.7K | 0 |
| Nov 28, 2025↗ | Ferrari Mauro | Director | Sell | 8,750 | $56.39 | $493.4K | 0 |
| Oct 1, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Sep 12, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $30.00 | $450.0K | 0 |
| Sep 2, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $25.00 | $375.0K | 0 |
| Aug 13, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 10,000 | $20.00 | $200.0K | 0 |
| Apr 9, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 141,122 | $10.87 | $1.53M | 0 |
| Mar 13, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,425 | $15.07 | $775.0K | 0 |
| Mar 3, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 300,000 | $17.58 | $5.27M | 0 |
| Jan 23, 2025↗ | OLUKOTUN ADEOYE Y | Director | Sell | 959 | $21.00 | $20.1K | 0 |
| Jan 4, 2025↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 32,729 | $19.82 | $648.8K | 0 |
| Jan 4, 2025↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 45,167 | $19.77 | $893.1K | 0 |
| Jan 4, 2025↗ | O'Brien Patrick | COO and General Counsel | Sell | 37,184 | $19.80 | $736.1K | 0 |
| Jan 2, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 11,520 | $19.05 | $219.5K | 0 |
| Dec 27, 2024↗ | OLUKOTUN ADEOYE Y | Director | Sell | 2,850 | $20.00 | $57.0K | 0 |
| Dec 23, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,563 | $19.59 | $246.1K | 0 |
| Dec 18, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,712 | $21.24 | $567.5K | 0 |
| Dec 16, 2024↗ | GIVEN DOUGLAS B | Director | Sell | 5,547 | $21.91 | $121.6K | 0 |
| Dec 16, 2024↗ | Vakiener Victoria | Director | Sell | 8,994 | $21.91 | $197.1K | 0 |
| Dec 16, 2024↗ | Waddill William D. | Director | Sell | 7,495 | $21.97 | $164.7K | 0 |
| Jul 2, 2024↗ | Oliver Tracie | Chief Commercial Officer | Sell | 9,394 | $25.28 | $237.5K | 0 |
| May 2, 2024↗ | Vakiener Victoria | Director | Sell | 1,799 | $23.31 | $41.9K | 0 |
| Apr 1, 2024↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 6,000 | $28.03 | $168.2K | 0 |
| Mar 18, 2024↗ | Lu Hongbo | Director | Buy | 3,000 | $27.66 | $83.0K | 0 |
| Mar 6, 2024↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $35.19 | $1.41M | 0 |
| Jan 31, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,499 | $32.35 | $1.86M | 0 |
| Jan 12, 2024↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 7,940 | $36.89 | $292.9K | 0 |
| Jan 11, 2024↗ | Ferrari Mauro | Director | Sell | 3,147 | $38.06 | $119.8K | 0 |
| Jan 11, 2024↗ | GIVEN DOUGLAS B | Director | Sell | 2,911 | $38.06 | $110.8K | 0 |
| Jan 11, 2024↗ | Vakiener Victoria | Director | Sell | 4,720 | $38.10 | $179.8K | 0 |
| Jan 11, 2024↗ | Waddill William D. | Director | Sell | 3,934 | $38.07 | $149.8K | 0 |
| Jan 4, 2024↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 16,104 | $35.27 | $567.9K | 0 |
| Jan 4, 2024↗ | Oliver Tracie | Chief Commercial Officer | Sell | 74 | $33.89 | $2.5K | 0 |
| Jan 4, 2024↗ | San Martin Javier | Chief Medical Officer | Sell | 8,303 | $35.26 | $292.8K | 0 |
| Jan 3, 2024↗ | Hamilton James C | Insider | Sell | 38,443 | $34.69 | $1.33M | 0 |
| Jan 3, 2024↗ | O'Brien Patrick | COO and General Counsel | Sell | 33,190 | $34.36 | $1.14M | 0 |
| Jan 2, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 9,952 | $31.01 | $308.6K | 0 |
| Dec 20, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,000 | $28.54 | $342.5K | 0 |
| Nov 20, 2023↗ | San Martin Javier | Chief Medical Officer | Sell | 19,700 | $28.80 | $567.3K | 0 |
| Oct 25, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 24,338 | $24.21 | $589.2K | 0 |
| Sep 28, 2023↗ | Vakiener Victoria | Director | Sell | 1,550 | $26.33 | $40.8K | 0 |
| Sep 18, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,755 | $28.12 | $1.62M | 0 |
| Jul 3, 2023↗ | Oliver Tracie | Chief Commercial Officer | Sell | 8,925 | $35.31 | $315.1K | 0 |
| Jun 30, 2023↗ | Hamilton James C | Insider | Sell | 3,000 | $35.53 | $106.6K | 0 |
| Jun 27, 2023↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 15,000 | $36.20 | $543.0K | 0 |
| May 5, 2023↗ | GIVEN DOUGLAS B | Director | Sell | 6,500 | $40.90 | $265.9K | 0 |
| May 3, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 104,928 | $39.32 | $4.13M | 0 |
| Mar 3, 2023↗ | OLUKOTUN ADEOYE Y | Director | Sell | 11,350 | $32.65 | $370.6K | 0 |
| Feb 27, 2023↗ | GIVEN DOUGLAS B | Director | Sell | 875 | $32.62 | $28.5K | 0 |
| Jan 9, 2023↗ | Waddill William D. | Director | Sell | 3,200 | $30.00 | $96.0K | 0 |
| Jan 5, 2023↗ | Hamilton James C | Insider | Sell | 13,803 | $37.40 | $516.2K | 0 |
| Jan 5, 2023↗ | O'Brien Patrick | COO and General Counsel | Sell | 15,000 | $37.39 | $560.9K | 0 |
| Jan 3, 2023↗ | Hamilton James C | Insider | Sell | 10,338 | $38.38 | $396.7K | 0 |
| Jan 3, 2023↗ | O'Brien Patrick | COO and General Counsel | Sell | 17,500 | $38.33 | $670.8K | 0 |
| Dec 29, 2022↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 30,625 | $40.00 | $1.23M | 0 |
| Nov 21, 2022↗ | San Martin Javier | Chief Medical Officer | Sell | 19,500 | $29.99 | $584.7K | 0 |
| Feb 11, 2022↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 146,388 | $51.91 | $7.60M | 0 |
| Jan 5, 2022↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $61.70 | $2.47M | 0 |
| Jan 5, 2022↗ | O'Brien Patrick | General Counsel | Sell | 32,500 | $61.72 | $2.01M | 0 |
| Jan 4, 2022↗ | Hamilton James C | Insider | Sell | 25,625 | $64.57 | $1.65M | 0 |
| Jan 3, 2022↗ | De Backer Marianne | Director | Sell | 4,500 | $64.71 | $291.2K | 0 |
| Jan 3, 2022↗ | OLUKOTUN ADEOYE Y | Director | Sell | 4,050 | $64.75 | $262.2K | 0 |
| Jan 3, 2022↗ | PERRY MICHAEL S | Director | Sell | 4,500 | $64.71 | $291.2K | 0 |
| Jan 3, 2022↗ | Waddill William D. | Director | Sell | 4,500 | $64.72 | $291.2K | 0 |
| Dec 28, 2021↗ | Ferrari Mauro | Director | Sell | 3,400 | $66.82 | $227.2K | 0 |
| Dec 28, 2021↗ | GIVEN DOUGLAS B | Director | Buy | 655 | $66.37 | $43.5K | 0 |
| Dec 15, 2021↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 60,000 | $67.56 | $4.05M | 0 |
| Nov 19, 2021↗ | San Martin Javier | Chief Medical Officer | Sell | 19,500 | $69.31 | $1.35M | 0 |
| Oct 20, 2021↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 65,000 | $65.77 | $4.27M | 0 |
| Sep 13, 2021↗ | OLUKOTUN ADEOYE Y | Director | Sell | 5,000 | $63.76 | $318.8K | 0 |
| Sep 9, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 5,000 | $65.24 | $326.2K | 0 |
| Jun 24, 2021↗ | De Backer Marianne | Director | Sell | 5,000 | $89.85 | $449.3K | 0 |
| Jun 22, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 4,500 | $89.21 | $401.4K | 0 |
| Jun 22, 2021↗ | Hassard James | Chief Commercial Officer | Sell | 3,625 | $89.22 | $323.4K | 0 |
| Feb 22, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 1,125 | $88.73 | $99.8K | 0 |
ARWR Insider Buying Activity
The following table shows recent insider purchases of Arrowhead Pharmaceuticals, Inc. (ARWR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2024↗ | Lu Hongbo | Director | Buy | 3,000 | $27.66 | $83.0K | 0 |
| Dec 28, 2021↗ | GIVEN DOUGLAS B | Director | Buy | 655 | $66.37 | $43.5K | 0 |
ARWR Insider Selling Activity
The following table shows recent insider sales of Arrowhead Pharmaceuticals, Inc. (ARWR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026↗ | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $64.19 | $641.9K | 236,958 |
| Jan 5, 2026↗ | Anzalone Christopher Richard | director, officer: Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 3,798,510 |
| Jan 5, 2026↗ | Hamilton James C | officer: Chief Medical Officer | Sell | 80,328 | $63.11 | $5.07M | 207,497 |
| Jan 5, 2026↗ | O'Brien Patrick | officer: COO | Sell | 48,593 | $63.12 | $3.07M | 520,033 |
| Jan 2, 2026↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 0 |
| Dec 31, 2025↗ | O'Brien Patrick | COO | Sell | 49,493 | $63.11 | $3.12M | 0 |
| Dec 29, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,726 | $69.13 | $3.58M | 0 |
| Dec 26, 2025↗ | Ferrari Mauro | Director | Sell | 7,530 | $70.00 | $527.1K | 0 |
| Dec 19, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,031 | $68.04 | $1.77M | 0 |
| Dec 19, 2025↗ | OLUKOTUN ADEOYE Y | Director | Sell | 10,000 | $67.66 | $676.6K | 0 |
| Dec 19, 2025↗ | Vakiener Victoria | Director | Sell | 10,040 | $67.68 | $679.5K | 0 |
| Dec 19, 2025↗ | Waddill William D. | Director | Sell | 8,367 | $67.65 | $566.0K | 0 |
| Dec 17, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 85,000 | $64.04 | $5.44M | 0 |
| Dec 12, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 184,298 | $67.00 | $12.35M | 0 |
| Dec 5, 2025↗ | PERRY MICHAEL S | Director | Sell | 16,250 | $61.03 | $991.7K | 0 |
| Nov 28, 2025↗ | Ferrari Mauro | Director | Sell | 8,750 | $56.39 | $493.4K | 0 |
| Oct 1, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Sep 12, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $30.00 | $450.0K | 0 |
| Sep 2, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $25.00 | $375.0K | 0 |
| Aug 13, 2025↗ | Hamilton James C | Chief Medical Officer | Sell | 10,000 | $20.00 | $200.0K | 0 |
| Apr 9, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 141,122 | $10.87 | $1.53M | 0 |
| Mar 13, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,425 | $15.07 | $775.0K | 0 |
| Mar 3, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 300,000 | $17.58 | $5.27M | 0 |
| Jan 23, 2025↗ | OLUKOTUN ADEOYE Y | Director | Sell | 959 | $21.00 | $20.1K | 0 |
| Jan 4, 2025↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 32,729 | $19.82 | $648.8K | 0 |
| Jan 4, 2025↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 45,167 | $19.77 | $893.1K | 0 |
| Jan 4, 2025↗ | O'Brien Patrick | COO and General Counsel | Sell | 37,184 | $19.80 | $736.1K | 0 |
| Jan 2, 2025↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 11,520 | $19.05 | $219.5K | 0 |
| Dec 27, 2024↗ | OLUKOTUN ADEOYE Y | Director | Sell | 2,850 | $20.00 | $57.0K | 0 |
| Dec 23, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,563 | $19.59 | $246.1K | 0 |
| Dec 18, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,712 | $21.24 | $567.5K | 0 |
| Dec 16, 2024↗ | GIVEN DOUGLAS B | Director | Sell | 5,547 | $21.91 | $121.6K | 0 |
| Dec 16, 2024↗ | Vakiener Victoria | Director | Sell | 8,994 | $21.91 | $197.1K | 0 |
| Dec 16, 2024↗ | Waddill William D. | Director | Sell | 7,495 | $21.97 | $164.7K | 0 |
| Jul 2, 2024↗ | Oliver Tracie | Chief Commercial Officer | Sell | 9,394 | $25.28 | $237.5K | 0 |
| May 2, 2024↗ | Vakiener Victoria | Director | Sell | 1,799 | $23.31 | $41.9K | 0 |
| Apr 1, 2024↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 6,000 | $28.03 | $168.2K | 0 |
| Mar 6, 2024↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $35.19 | $1.41M | 0 |
| Jan 31, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,499 | $32.35 | $1.86M | 0 |
| Jan 12, 2024↗ | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 7,940 | $36.89 | $292.9K | 0 |
| Jan 11, 2024↗ | Ferrari Mauro | Director | Sell | 3,147 | $38.06 | $119.8K | 0 |
| Jan 11, 2024↗ | GIVEN DOUGLAS B | Director | Sell | 2,911 | $38.06 | $110.8K | 0 |
| Jan 11, 2024↗ | Vakiener Victoria | Director | Sell | 4,720 | $38.10 | $179.8K | 0 |
| Jan 11, 2024↗ | Waddill William D. | Director | Sell | 3,934 | $38.07 | $149.8K | 0 |
| Jan 4, 2024↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 16,104 | $35.27 | $567.9K | 0 |
| Jan 4, 2024↗ | Oliver Tracie | Chief Commercial Officer | Sell | 74 | $33.89 | $2.5K | 0 |
| Jan 4, 2024↗ | San Martin Javier | Chief Medical Officer | Sell | 8,303 | $35.26 | $292.8K | 0 |
| Jan 3, 2024↗ | Hamilton James C | Insider | Sell | 38,443 | $34.69 | $1.33M | 0 |
| Jan 3, 2024↗ | O'Brien Patrick | COO and General Counsel | Sell | 33,190 | $34.36 | $1.14M | 0 |
| Jan 2, 2024↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 9,952 | $31.01 | $308.6K | 0 |
| Dec 20, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,000 | $28.54 | $342.5K | 0 |
| Nov 20, 2023↗ | San Martin Javier | Chief Medical Officer | Sell | 19,700 | $28.80 | $567.3K | 0 |
| Oct 25, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 24,338 | $24.21 | $589.2K | 0 |
| Sep 28, 2023↗ | Vakiener Victoria | Director | Sell | 1,550 | $26.33 | $40.8K | 0 |
| Sep 18, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,755 | $28.12 | $1.62M | 0 |
| Jul 3, 2023↗ | Oliver Tracie | Chief Commercial Officer | Sell | 8,925 | $35.31 | $315.1K | 0 |
| Jun 30, 2023↗ | Hamilton James C | Insider | Sell | 3,000 | $35.53 | $106.6K | 0 |
| Jun 27, 2023↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 15,000 | $36.20 | $543.0K | 0 |
| May 5, 2023↗ | GIVEN DOUGLAS B | Director | Sell | 6,500 | $40.90 | $265.9K | 0 |
| May 3, 2023↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 104,928 | $39.32 | $4.13M | 0 |
| Mar 3, 2023↗ | OLUKOTUN ADEOYE Y | Director | Sell | 11,350 | $32.65 | $370.6K | 0 |
| Feb 27, 2023↗ | GIVEN DOUGLAS B | Director | Sell | 875 | $32.62 | $28.5K | 0 |
| Jan 9, 2023↗ | Waddill William D. | Director | Sell | 3,200 | $30.00 | $96.0K | 0 |
| Jan 5, 2023↗ | Hamilton James C | Insider | Sell | 13,803 | $37.40 | $516.2K | 0 |
| Jan 5, 2023↗ | O'Brien Patrick | COO and General Counsel | Sell | 15,000 | $37.39 | $560.9K | 0 |
| Jan 3, 2023↗ | Hamilton James C | Insider | Sell | 10,338 | $38.38 | $396.7K | 0 |
| Jan 3, 2023↗ | O'Brien Patrick | COO and General Counsel | Sell | 17,500 | $38.33 | $670.8K | 0 |
| Dec 29, 2022↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 30,625 | $40.00 | $1.23M | 0 |
| Nov 21, 2022↗ | San Martin Javier | Chief Medical Officer | Sell | 19,500 | $29.99 | $584.7K | 0 |
| Feb 11, 2022↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 146,388 | $51.91 | $7.60M | 0 |
| Jan 5, 2022↗ | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $61.70 | $2.47M | 0 |
| Jan 5, 2022↗ | O'Brien Patrick | General Counsel | Sell | 32,500 | $61.72 | $2.01M | 0 |
| Jan 4, 2022↗ | Hamilton James C | Insider | Sell | 25,625 | $64.57 | $1.65M | 0 |
| Jan 3, 2022↗ | De Backer Marianne | Director | Sell | 4,500 | $64.71 | $291.2K | 0 |
| Jan 3, 2022↗ | OLUKOTUN ADEOYE Y | Director | Sell | 4,050 | $64.75 | $262.2K | 0 |
| Jan 3, 2022↗ | PERRY MICHAEL S | Director | Sell | 4,500 | $64.71 | $291.2K | 0 |
| Jan 3, 2022↗ | Waddill William D. | Director | Sell | 4,500 | $64.72 | $291.2K | 0 |
| Dec 28, 2021↗ | Ferrari Mauro | Director | Sell | 3,400 | $66.82 | $227.2K | 0 |
| Dec 15, 2021↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 60,000 | $67.56 | $4.05M | 0 |
| Nov 19, 2021↗ | San Martin Javier | Chief Medical Officer | Sell | 19,500 | $69.31 | $1.35M | 0 |
| Oct 20, 2021↗ | Anzalone Christopher Richard | Chief Executive Officer | Sell | 65,000 | $65.77 | $4.27M | 0 |
| Sep 13, 2021↗ | OLUKOTUN ADEOYE Y | Director | Sell | 5,000 | $63.76 | $318.8K | 0 |
| Sep 9, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 5,000 | $65.24 | $326.2K | 0 |
| Jun 24, 2021↗ | De Backer Marianne | Director | Sell | 5,000 | $89.85 | $449.3K | 0 |
| Jun 22, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 4,500 | $89.21 | $401.4K | 0 |
| Jun 22, 2021↗ | Hassard James | Chief Commercial Officer | Sell | 3,625 | $89.22 | $323.4K | 0 |
| Feb 22, 2021↗ | GIVEN DOUGLAS B | Director | Sell | 1,125 | $88.73 | $99.8K | 0 |
ARWR Insiders
Anzalone Christopher Richard
director, officer: Chief Executive Officer
Sold $871.7K
2 tradesLast: Jan 2, 2026
Similar Stocks to ARWR
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B